2021
DOI: 10.1016/j.anndiagpath.2021.151701
|View full text |Cite
|
Sign up to set email alerts
|

Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
13
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(15 citation statements)
references
References 32 publications
2
13
0
Order By: Relevance
“…STAS is regarded as a significant risk factor for recurrence after surgery in patients with stage IA lung adenocarcinoma [16,17]. These result was in accordance with former later stage studies, in which PD-L1 expression was related to poor pathological subtype and prognosis in stage IA-IV lung cancer [18][19][20][21]. Thus, we believe PD-L1 pathway way be further involved to promote the pathological evolution of IAC.…”
Section: Discussionsupporting
confidence: 87%
“…STAS is regarded as a significant risk factor for recurrence after surgery in patients with stage IA lung adenocarcinoma [16,17]. These result was in accordance with former later stage studies, in which PD-L1 expression was related to poor pathological subtype and prognosis in stage IA-IV lung cancer [18][19][20][21]. Thus, we believe PD-L1 pathway way be further involved to promote the pathological evolution of IAC.…”
Section: Discussionsupporting
confidence: 87%
“…It is essential to realize that the variety of results and different prognostic impact of PD‐L1 in specific subgroups is influenced by the testing method itself (e.g., different antibodies and thresholds) and individual patient‐related characteristics, such as ethnicity or tumor histology. For instance, different proportions of PD‐L1‐positive tumors for distinct histological NSCLC subtypes have been reported 40–43 . In our study, high PD‐L1 TPS score carried both prognostic and predictive value in the ICI treated patients while in the whole cohort, including patients treated in curative settings, only the association between improved OS and CRP level of ≤10 was retained.…”
Section: Discussionmentioning
confidence: 50%
“…For instance, different proportions of PD-L1positive tumors for distinct histological NSCLC subtypes have been reported. [40][41][42][43] In our study, high PD-L1 TPS score carried both prognostic and predictive value in the ICI treated patients while in the whole cohort, including patients treated in curative settings, only the association between improved OS and CRP level of ≤10 was retained.…”
Section: Discussionmentioning
confidence: 63%
“…Thus, the expression of PD-L1 might provide a theoretical basis for the implementation of immunotherapy to treat NSCLC. Montero et al 32 showed that overexpression of the PD-L1 was associated with poor OS in NSCLC. Cancer cells inactivate T cells through PD-L1 expression; therefore, the higher the expression of PD-L1, the more the immune system is suppressed, which might lead to greater than expected cancer progression 33 .…”
Section: Discussionmentioning
confidence: 99%